International Journal of Gerontology
Volume 1, Issue 1 , Pages 2-9, March 2007

HB-EGF, Transactivation, and Cardiac Hypertrophy

  • Seiji Takashima

      Affiliations

    • Department of Cardiovascular Medicine, Graduate School of Medicine and Health Care Center, Osaka University, Osaka, Japan
    • ,
  • Masafumi Kitakaze

      Affiliations

    • Cardiovascular Division of Medicine, National Cardiovascular Center of Japan, Suita, Osaka, Japan
    • Corresponding Author InformationCorrespondence to: Dr Masafumi Kitakaze, Cardiovascular Division of Medicine, National Cardiovascular Center of Japan, 5-7-1 Fujishiro-dai, Suita, Osaka 565-8565, Japan

Accepted 1 December 2006.

Article Outline

SUMMARY 

Transactivation of epidermal growth factor receptor (EGFR) family ligands by G protein coupled receptor (GPCR) agonist plays important roles in many physiologic activities. In the heart, heparin-binding EGF-like growth factor (HB-EGF), which is one of the EGF family ligands, is an indispensable molecule for cardiac cell metabolism. Membrane-anchored HB-EGF is released by GPCR agonist stimulation and moves signals leading to hypertrophy. Amelioration of this signal transduction by HB-EGF genome deletion causes severe heart dysfunction, indicating the important role of HB-EGF in the heart. Cleavage of HB-EGF was mediated by activation of membrane-anchored metalloprotease. Inhibitor of metalloprotease prevents activation of HB-EGF andattenuates hypertrophic response of cardiomyocytes by GPCR agonists such as angiotensin II or catecholamine. These data strongly suggest that HB-EGF is involved in cardiac development and metabolism. The physiologicand clinical roles of EGF family ligands in the heart are reviewed.

Key Words:  cardiac hypertrophy , heart failure , HB-EGF , metalloprotease

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Hynes NE , Lane HA . ERBB receptors and cancer: the complexity of targeted inhibitors . Natl Rev Cancer . 2005;5:341–354
  2. Corwin HL , Gettinger A , Pearl RG , Fink MP , Levy MM , Shapiro MJ , et al.   Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial . JAMA . 2002;288:2827–2835
  3. Antman KH . G-CSF and GM-CSF in clinical trials . Yale J Biol Med . 1990;63:387–410
  4. Kalb R . The protean actions of neurotrophins and their receptors on the life and death of neurons . Trends Neurosci . 2005;28:5–11
  5. Pasumarthi KB , Field LJ . Cardiomyocyte cell cycle regulation . Circ Res . 2002;90:1044–1054
  6. Olayioye MA , Neve RM , Lane HA , Hynes NE . The ErbB signaling network: receptor heterodimerization in development and cancer . EMBO J . 2000;19:3159–3167
  7. Tzahar E , Yarden Y . The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands . Biochim Biophys Acta . 1998;1377:M25–M37
  8. Higashiyama S , Lau K , Besner GE , Abraham JA , Klagsbrun M . Structure of heparin-binding EGF-like growth factor. Multiple forms, primary structure, and glycosylation of the mature protein . J Biol Chem . 1992;267:6205–6212
  9. Higashiyama S , Abraham JA , Miller J , Fiddes JC , Klagsbrun M . A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF . Science . 1991;251:936–939
  10. Goishi K , Higashiyama S , Klagsbrun M , Nakano N , Umata T , Ishikawa M , et al.   Phorbol ester induces the rapid processing of cell surface heparin-binding EGF-like growth factor: conversion from juxtacrine to paracrine growth factor activity . Mol Biol Cell . 1995;6:967–980
  11. Fan H , Derynck R . Ectodomain shedding of TGF-alpha and other transmembrane proteins is induced by receptor tyrosine kinase activation and MAP kinase signaling cascades . EMBO J . 1999;18:6962–6972
  12. Sternlicht MD , Sunnarborg SW , Kouros-Mehr H , Yu Y , Lee DC , Werb Z . Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17 dependent shedding of epithelial amphiregulin . Development . 2005;132:3923–3933
  13. Montero JC , Yuste L , Diaz-Rodriguez E , Esparis-Ogando A , Pandiella A . Differential shedding of transmembrane neuregulin isoforms by the tumor necrosis factoralpha-converting enzyme . Mol Cell Neurosci . 2000;16:631–648
  14. Higashiyama S , Iwamoto R , Goishi K , Raab G , Taniguchi N , Klagsbrun M , et al.   The membrane protein CD9/DRAP 27 potentiates the juxtacrine growth factor activity of the membrane-anchored heparin-binding EGF-like growth factor . J Cell Biol . 1995;128:929–938
  15. Iwamoto R , Mekada E . Heparin-binding EGF-like growth factor: a juxtacrine growth factor . Cytokine Growth Factor Rev . 2000;11:335–344
  16. Iwamoto R , Handa K , Mekada E . Contact-dependent growth inhibition and apoptosis of epidermal growth factor (EGF) receptor-expressing cells by the membraneanchored form of heparin-binding EGF-like growth factor . J Biol Chem . 1999;274:25906–25912
  17. Mitamura T , Iwamoto R , Umata T , Yomo T , Urabe I , Tsuneoka M , et al.   The 27-kD diphtheria toxin receptorassociated protein (DRAP27) from vero cells is the monkey homologue of human CD9 antigen: expression of DRAP27 elevates the number of diphtheria toxin receptors on toxin-sensitive cells . J Cell Biol . 1992;118:1389–1399
  18. Iwamoto R , Higashiyama S , Mitamura T , Taniguchi N , Klagsbrun M , Mekada E . Heparin-binding EGF-like growth factor, which acts as the diphtheria toxin receptor, forms a complex with membrane protein DRAP27/CD9, which up-regulates functional receptors and diphtheria toxin sensitivity . EMBO J . 1994;13:2322–2330
  19. Naglich JG , Metherall JE , Russell DW , Eidels L . Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor . Cell . 1992;69:1051–1061
  20. Higashiyama S , Abraham JA , Klagsbrun M . Heparinbinding EGF-like growth factor stimulation of smooth muscle cell migration: dependence on interactions with cell surface heparan sulfate . J Cell Biol . 1993;122:933–940
  21. Raab G , Klagsbrun M . Heparin-binding EGF-like growth factor . Biochim Biophys Acta . 1997;1333:F179–F199
  22. Marikovsky M , Breuing K , Liu PY , Eriksson E , Higashiyama S , Farber P , et al.   Appearance of heparin-binding EGF-like growth factor in wound fluid as a response to injury . Proc Natl Acad Sci USA . 1993;90:3889–3893
  23. Tokumaru S , Higashiyama S , Endo T , Nakagawa T , Miyagawa JI , Yamamori K , et al.   Ectodomain shedding of epidermal growth factor receptor ligands is required for keratinocyte migration in cutaneous wound healing . J Cell Biol . 2000;151:209–220
  24. Asakura M , Kitakaze M , Takashima S , Liao Y , Ishikura F , Yoshinaka T , et al.   Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy . Nat Med . 2002;8:35–40
  25. Miyagawa J , Higashiyama S , Kawata S , Inui Y , Tamura S , Yamamoto K , et al.   Localization of heparin-binding EGF-like growth factor in the smooth muscle cells and macrophages of human atherosclerotic plaques . J Clin Invest . 1995;95:404–411
  26. Takemura T , Hino S , Kuwajima H , Yanagida H , Okada M , Nagata M , et al.   Induction of collecting duct morphogenesis in vitro by heparin-binding epidermal growth factor-like growth factor . J Am Soc Nephrol . 2001;12:964–972
  27. Das SK , Wang XN , Paria BC , Damm D , Abraham JA , Klagsbrun M , et al.   Heparin-binding EGF-like growth factor gene is induced in the mouse uterus temporally by the blastocyst solely at the site of its apposition: a possible ligand for interaction with blastocyst EGF-receptor in implantation . Development . 1994;120:1071–1083
  28. Lemjabbar H , Basbaum C . Platelet-activating factor receptor and ADAM10 mediate responses to Staphylococcus aureus in epithelial cells . Nat Med . 2002;8:41–46
  29. Fu S , Bottoli I , Goller M , Vogt PK . Heparin-binding epidermal growth factor-like growth factor, a v-Jun target gene, induces oncogenic transformation . Proc Natl Acad Sci USA . 1999;96:5716–5721
  30. Chen B , Bronson RT , Klaman LD , Hampton TG , Wang JF , Green PJ , et al.   Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis . Nat Genet . 2000;24:296–299
  31. Lee KF , Simon H , Chen H , Bates B , Hung MC , Hauser C . Requirement for neuregulin receptor erbB2 in neural and cardiac development . Nature . 1995;378:394–398
  32. Meyer D , Birchmeier C . Multiple essential functions of neuregulin in development . Nature . 1995;378:386–390
  33. Erickson SL , O'Shea KS , Ghaboosi N , Loverro L , Frantz G , Bauer M , et al.   ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2 and heregulin-deficient mice . Development . 1997;124:4999–5011
  34. Ozcelik C , Erdmann B , Pilz B , Wettschureck N , Britsch S , Hubner N , et al.   Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy . Proc Natl Acad Sci USA . 2002;99:8880–8885
  35. Crone SA , Zhao YY , Fan L , Gu Y , Minamisawa S , Liu Y , et al.   ErbB2 is essential in the prevention of dilated cardiomyopathy . Nat Med . 2002;8:459–465
  36. Prenzel N , Zwick E , Daub H , Leserer M , Abraham R , Wallasch C , et al.   EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF . Nature . 1999;402:884–888
  37. Daub H , Weiss FU , Wallasch C , Ullrich A . Role of transactivation of the EGF receptor in signaling by G-proteincoupled receptors . Nature . 1996;379:557–560
  38. Adams JW , Brown JH . G-proteins in growth and apoptosis: lessons from the heart . Oncogene . 2001;20:1626–1634
  39. Kudoh S , Komuro I , Hiroi Y , Zou Y , Harada K , Sugaya T , et al.   Mechanical stretch induces hypertrophic responses in cardiac myocytes of angiotensin II type 1a receptor knockout mice . J Biol Chem . 1998;273:24037–24043
  40. Thomas WG , Brandenburger Y , Autelitano DJ , Pham T , Qian H , Hannan RD . Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor . Circ Res . 2002;90:135–142
  41. Fickova M . Structure and activation of EGF receptor: minireview . Endocr Regul . 2002;36:87–93
  42. Cho HS , Mason K , Ramyar KX , Stanley AM , Gabelli SB , Denney DW , et al.   Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab . Nature . 2003;421:756–760
  43. Cho HS , Leahy DJ . Structure of the extracellular region of HER3 reveals an interdomain tether . Science . 2002;297:1330–1333
  44. Perez DM , Karnik SS . Multiple signaling states of G-protein-coupled receptors . Pharmacol Rev . 2005;57:147–161
  45. Eguchi S , Inagami T . Signal transduction of angiotensin II type 1 receptor through receptor tyrosine kinase . Regul Pept . 2000;91:13–20
  46. Kim S , Iwao H . Activation of mitogen-activated protein kinases in cardiovascular hypertrophy and remodeling . Jpn J Pharmacol . 1999;80:97–102
  47. Saito S , Frank GD , Motley ED , Dempsey PJ , Utsunomiya H , Inagami T , et al.   Metalloprotease inhibitor blocks angiotensin II-induced migration through inhibition of epidermal growth factor receptor transactivation . Biochem Biophys Res Commun . 2002;294:1023–1029
  48. Zwick E , Bange J , Ullrich A . Receptor tyrosine kinases as targets for anticancer drugs . Trends Mol Med . 2002;8:17–23
  49. Schlessinger J . Ligand-induced, receptor-mediated dimerization and activation of EGF receptor . Cell . 2002;110:669–672
  50. Dethlefsen SM , Raab G , Moses MA , Adam RM , Klagsbrun M , Freeman MR . Extracellular calcium influx stimulates metalloproteinase cleavage and secretion of heparinbinding EGF-like growth factor independently of protein kinase C . J Cell Biochem . 1998;69:143–153
  51. Hirata M , Umata T , Takahashi T , Ohnuma M , Miura Y , Iwamoto R , et al.   Identification of serum factor inducing ectodomain shedding of proHB-EGF and studies of noncleavable mutants of proHB-EGF . Biochem Biophys Res Commun . 2001;283:915–922
  52. Gechtman Z , Alonso JL , Raab G , Ingber DE , Klagsbrun M . The shedding of membrane-anchored heparin-binding epidermal-like growth factor is regulated by the Raf/ mitogen-activated protein kinase cascade and by cell adhesion and spreading . J Biol Chem . 1999;274:28828–28835
  53. Izumi Y , Hirata M , Hasuwa H , Iwamoto R , Umata T , Miyado K , et al.   A metalloprotease-disintegrin, MDC9/ meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membraneanchored heparin-binding EGF-like growth factor . EMBO J . 1998;17:7260–7272
  54. Suzuki M , Raab G , Moses MA , Fernandez CA , Klagsbrun M . Matrix metalloproteinase-3 releases active heparinbinding EGF-like growth factor by cleavage at a specific juxtamembrane site . J Biol Chem . 1997;272:31730–31737
  55. Sunnarborg SW , Hinkle CL , Stevenson M , Russell WE , Raska CS , Peschon JJ , et al.   Tumor necrosis factor-alpha converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability . J Biol Chem . 2002;277:12838–12845
  56. Yan Y , Shirakabe K , Werb Z . The metalloprotease Kuzbanian (ADAM10) mediates the transactivation of EGF receptor by G protein-coupled receptors . J Cell Biol . 2002;158:221–226
  57. Yu WH , Woessner JF , McNeish JD , Stamenkovic I . CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling . Genes Dev . 2002;16:307–323
  58. Yamazaki S , Iwamoto R , Saeki K , Asakura M , Takashima S , Yamazaki A , et al.   Mice with defects in HB-EGF ectodomain shedding show severe developmental abnormalities . J Cell Biol . 2003;163:469–475
  59. Iwamoto R , Yamazaki S , Asakura M , Takashima S , Hasuwa H , Miyado K , et al.   Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function . Proc Natl Acad Sci USA . 2003;100:3221–3226
  60. Beerli RR , Hynes NE . Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities . J Biol Chem . 1996;271:6071–6076
  61. Feldman AM , Lorell BH , Reis SE . Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity . Circulation . 2000;102:272–274
  62. Cittadini A , Isgaard J , Monti MG , Casaburi C , Di Gianni A , Serpico R , et al.   Growth hormone prolongs survival in experimental postinfarction heart failure . J Am Coll Cardiol . 2003;41:2154–2163
  63. Dreifuss P . Congestive heart failure and the growth hormone/insulin-like growth factor-1 (GH/IGF-1) system . Am J Cardiol . 2003;92:245–246

PII: S1873-9598(08)70018-8

doi:10.1016/S1873-9598(08)70018-8

International Journal of Gerontology
Volume 1, Issue 1 , Pages 2-9, March 2007

Article Tools